TRP_1170x120_12-19-19

CutisPharma inaugurates new R&D center

Print Friendly, PDF & Email
WILMINGTON, Mass. — CutisPharma has opened a new research-and-development center in Woburn, Mass., to house the specialty pharmaceutical company’s expanding R&D team.

CutisPharma said the new center will provide office and laboratory space to facilitate the development of products for Food and Drug Administration approval under its RM Therapeutics subsidiary.

cutispharma_woburn-rd-center-opening

Massachusetts State Senator Bruce Tarr cuts the ribbon for the new R&D center with CutisPharma’s Steve Dinh and CEO Neal Muni.

“We are in the midst of a significant expansion of our research and development capabilities,” stated Steven Dinh, executive vice president and chief scientific officer at CutisPharma. “Our new state-of-the-art R&D center provides us sufficient space to accommodate our growing team as well as significantly enhanced capacity to do in-house research with our additional laboratory.”

CutisPharma showcased the new R&D facility at a grand opening event this week attended by Massachusetts State Sen. Bruce Tarr and other state and local officials.

The Woburn R&D center is located less than mile from CutisPharma’s headquarters in Wilmington.

“Our state has quickly and definitively become the epicenter for life sciences because of substantial capital investments in research and development,” commented Tarr. “I applaud CutisPharma’s initiatives to expand here because they directly impact gains in local employment, enhancements of the region’s economy and ultimately the development of pharmaceuticals that can promote health.”

CutisPharma noted that the opening of the R&D facility builds on recent efforts to transition its business from its pharmacy compounding market base toward the development and commercialization of FDA-approved drugs.

In March, CutisPharma announced the opening of a manufacturing center at its Wilmington facility and the completion of supporting activities to ready the first New Drug Application (NDA) filing of its lead pipeline drug, RM-01, next year. In April, the company unveiled a partnership with Dr. Reddy’s Laboratories to acceleration the FDA approval process for three additional drugs, RM-02, RM-03 and RM-06.


EMC_728x90

TRP_728x90_12-19-19

Comments are closed.